Drug Trial Radar · NCT01170221
TR-701 FA vs. Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections.
Last checked: Nov 20, 2026Latest source record: Aug 29, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
667
Actual
Start
Aug 15, 2010
Primary completion
Sep 30, 2011
Study completion Sep 30, 2011
Sponsor
- Lead sponsor
- Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)Industry
- Sponsor type
- Industry
- First posted
- Jul 27, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, double dummy, multicenter Phase 3 study of oral TR-701 FA 200 mg once daily for 6 days versus oral Zyvox® (linezolid) 600 mg every 12 hours for 10 days for the treatment of ABSSSI in adults. Approximately 75 to 100 sites globally will participate in this study. Patients with an ABSSSI caused by suspected or documented gram positive pathogen(s) at baseline will be randomized 1:1 to study treatment
Conditions
- Skin and Subcutaneous Tissue Bacterial Infections
Interventions
TR-701 FADrug
Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
LinezolidDrug
Oral Linezolid 600 mg twice daily for 10 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Early Clinical Response RateTime frame: 48-72 hours
Locations
84 sites in 11 countries. Site status is shown where the registry gives one.
Trius investigator site 109
Dothan, Alabama
Trius Investigator site 130
Anaheim, California
Trius investigator site 118
Anaheim, California
Trius investigator site 129
Buena Park, California
Trius Investigator Site 103
Chula Vista, California
Trius Investigator Site 105
La Mesa, California
Trius investigator site 126
Laguna Beach, California
Trius investigator site 125
Norwalk, California
Trius Investigator Site 104
Oceanside, California
Trius investigator site 113
Oxnard, California
Trius investigator site 123
Pasadena, California
Trius Investigator Site 106
Rolling Hills Estates, California
Trius investigator site 111
Torrance, California
Trius investigator site 132
Torrance, California
Trius investigator site 127
Fort Lauderdale, Florida
Trius investigator site 135
Hialeah, Florida
Trius investigator site 101
Columbus, Georgia
Trius Investigator Site 102
Savannah, Georgia
Trius Investigator site 116
Chicago, Illinois
Trius Investigator Site 108
Springfield, Illinois
Trius investigator site 112
Evansville, Indiana
Trius Investigator Site 107
Detroit, Michigan
Trius investigator site 133
Butte, Montana
Trius investigator site 128
Las Vegas, Nevada
Trius investigator site 115
Somers Point, New Jersey
Trius investigator site 114
Toledo, Ohio
Trius investigator site 122
Houston, Texas
Trius investigator site 120
Houston, Texas
Trius investigator site 131
Houston, Texas
Trius Investigator site 121
Houston, Texas
Trius investigator site 309
Buenos Aires, Argentina
Trius investigator site 310
Buenos Aires, Argentina
Trius Investigator site 301
Córdoba, Argentina
Trius investigator site 305
Córdoba, Argentina
Trius investigator site 300
Córdoba, Argentina
Trius investigator site 308
Paraná, Argentina
Trius investigator site 303
Rosario, Argentina
Trius investigator site 306
Santa Fe, Argentina
Trius investigator site 307
Avellaneda, Pcia Buenos Aires, Argentina
Trius investigator site 304
Loma Hermosa, Pcia Buenos Aires, Argentina
Showing 40 of 84 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.